A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, nonrandomized, phase 1b study of TRC105 in combination
with standard dose treatment in patients with stage IV non-squamous non-small cell lung
cancer.